MX2012009748A - USO DE PEPTIDOS INHIBIDORES DEL FACTOR DE CRECIMIENTO TRANSFORMANTE-BETA1(TGF-ß1) PARA EL TRATAMIENTO DE FIBROSIS Y/U OPACIDAD CORNEAL. - Google Patents

USO DE PEPTIDOS INHIBIDORES DEL FACTOR DE CRECIMIENTO TRANSFORMANTE-BETA1(TGF-ß1) PARA EL TRATAMIENTO DE FIBROSIS Y/U OPACIDAD CORNEAL.

Info

Publication number
MX2012009748A
MX2012009748A MX2012009748A MX2012009748A MX2012009748A MX 2012009748 A MX2012009748 A MX 2012009748A MX 2012009748 A MX2012009748 A MX 2012009748A MX 2012009748 A MX2012009748 A MX 2012009748A MX 2012009748 A MX2012009748 A MX 2012009748A
Authority
MX
Mexico
Prior art keywords
tgf
beta
treatment
haze
growth factor
Prior art date
Application number
MX2012009748A
Other languages
English (en)
Spanish (es)
Inventor
Javier Dotor De Las Herrerias
Miguel Jose Maldonado Lopez
Original Assignee
Proyecto Biomedicina Cima Sl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proyecto Biomedicina Cima Sl filed Critical Proyecto Biomedicina Cima Sl
Publication of MX2012009748A publication Critical patent/MX2012009748A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2012009748A 2010-02-22 2011-02-21 USO DE PEPTIDOS INHIBIDORES DEL FACTOR DE CRECIMIENTO TRANSFORMANTE-BETA1(TGF-ß1) PARA EL TRATAMIENTO DE FIBROSIS Y/U OPACIDAD CORNEAL. MX2012009748A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/709,895 US8158589B2 (en) 2003-08-22 2010-02-22 Peptides with the capacity to bind to transforming growth factor β1 (TGF-β1)
PCT/EP2011/052543 WO2011101478A1 (en) 2010-02-22 2011-02-21 USE OF TRANSFORMING GROWTH FACTOR - BETA 1 (TGF-β1) INHIBITOR PEPTIDES FOR THE TREATMENT OF CORNEAL FIBROSIS AND/OR HAZE

Publications (1)

Publication Number Publication Date
MX2012009748A true MX2012009748A (es) 2012-12-05

Family

ID=43757920

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012009748A MX2012009748A (es) 2010-02-22 2011-02-21 USO DE PEPTIDOS INHIBIDORES DEL FACTOR DE CRECIMIENTO TRANSFORMANTE-BETA1(TGF-ß1) PARA EL TRATAMIENTO DE FIBROSIS Y/U OPACIDAD CORNEAL.

Country Status (10)

Country Link
US (2) US8158589B2 (enExample)
EP (1) EP2538962A1 (enExample)
JP (1) JP2013520405A (enExample)
CN (1) CN102791283A (enExample)
AU (1) AU2011217181A1 (enExample)
BR (1) BR112012020953A2 (enExample)
CA (1) CA2790625A1 (enExample)
MX (1) MX2012009748A (enExample)
RU (1) RU2012140704A (enExample)
WO (1) WO2011101478A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130158103A1 (en) * 2011-11-23 2013-06-20 The Curators Of The University Of Missouri Method of Tissue-Selective Targeted Gene Transfer
ES2423382B1 (es) * 2012-02-16 2014-07-15 Consejo Superior De Investigaciones Científicas (Csic) Inhibidor de la produccion de endoglina soluble y su aplicacion en patologias donde la endoglina soluble tiene un efecto patogenico
WO2013148155A1 (en) * 2012-03-26 2013-10-03 Digna Biotech Usa, Llc Compositions and methods for the treatment of dry eye disease
WO2014028862A1 (en) 2012-08-17 2014-02-20 Cornell University Use of dna in circulating exosomes as a diagnostic marker for metastasic disease
MX386503B (es) * 2013-07-30 2025-03-19 Kyoto Prefectural Public Univ Corp Medicamentos terapeuticos de matriz extracelular endotelial corneal.
WO2015064768A1 (ja) * 2013-10-31 2015-05-07 京都府公立大学法人 角膜内皮の小胞体細胞死関連疾患治療薬
CA2928626C (en) 2013-11-14 2023-03-14 The Doshisha Drug for treating corneal endothelium by promoting cell proliferation or inhibiting cell damage
US10844436B2 (en) 2014-04-01 2020-11-24 Cornell University Use of double-stranded DNA in exosomes: a novel biomarker in cancer detection
WO2016057702A2 (en) 2014-10-07 2016-04-14 Cornell University Methods for prognosing and preventing metastatic liver disease
WO2016172710A2 (en) 2015-04-24 2016-10-27 Cornell University Methods and reagents for determination and treatment of organotropic metastasis
JP7302120B2 (ja) * 2015-10-27 2023-07-04 タイペイ メディカル ユニバーシティ 線維症疾患の治療及び／又は予防用インドリン誘導体
JPWO2017110093A1 (ja) 2015-12-24 2018-10-11 学校法人同志社 ＴＧＦ−βシグナルに起因する障害を治療または予防するための医薬およびその応用
CN109844124B (zh) * 2016-05-20 2023-10-03 哈佛学院董事及会员团体 年龄相关疾病和病症的基因治疗方法
EP3659626A4 (en) 2017-07-26 2021-05-05 The Doshisha Drug for treating or preventing disorder caused by tgf- signalling, and application thereof
WO2019234221A1 (en) 2018-06-08 2019-12-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for stratification and treatment of a patient suffering from chronic lymphocytic leukemia
GB201908012D0 (en) * 2019-06-05 2019-07-17 Io Biotech Aps TGF-Beta vaccine
RU2700941C1 (ru) * 2019-07-05 2019-09-24 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр реабилитации и курортологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ РК" Минздрава России) Способ предупреждения развития помутнения роговицы при ее механических травмах
RU2701178C1 (ru) * 2019-07-10 2019-09-25 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр реабилитации и курортологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ РК" Минздрава России) Способ ускорения заживления роговицы при ее механических травмах
CN110483648A (zh) * 2019-08-27 2019-11-22 南京安吉生物科技有限公司 一种融合多肽及其应用
CN110862434B (zh) * 2019-10-28 2021-07-06 中山大学 一种可促进TGF-β1蛋白靶向降解的化合物及其制备方法与应用
JP2020073483A (ja) * 2019-10-30 2020-05-14 京都府公立大学法人 角膜内皮ｅｃｍ治療薬
AU2021409832A1 (en) * 2020-12-23 2023-08-10 Korea Institute Of Science And Technology NOVEL PEPTIDE CAPABLE OF INHIBITING TGF-β SIGNALING AND USE THEREOF
CN115040535B (zh) * 2022-08-15 2022-12-16 华南理工大学 硫酸化透明质酸在制备预防角膜纤维化、角膜瘢痕滴眼液中的应用
WO2026027520A1 (en) 2024-07-30 2026-02-05 Disit Biotech, S.L. Method of preparing parenteral formulations and formulations prepared therefrom

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4550022A (en) 1981-10-05 1985-10-29 Alcon Laboratories, Inc. Tissue irrigating solution
JPH08151396A (ja) 1994-11-28 1996-06-11 Teijin Ltd Ｈｌａ結合性オリゴペプチド及びそれを含有する免疫調節剤
AU5593398A (en) * 1996-12-05 1998-06-29 Alcon Laboratories, Inc. The use of inhibitors of tgf-beta's functions to ameliorate ocular pathology
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
ES2146552B1 (es) 1998-11-24 2001-04-16 Inst Cientifico Tecnol Navarra Peptidos inhibidores de tgf/31
US6399107B1 (en) 1998-12-22 2002-06-04 Alcon Laboratories, Inc. Use of inhibitors of gag synthesis for the treatment of corneal haze
EP1324767B1 (en) 2000-10-13 2009-06-24 The Johns Hopkins University Plasminogen activator to prevent corneal and subepithelial haze after laser vision correction surgery
ES2304069B1 (es) * 2003-08-22 2009-08-12 Proyecto De Biomedicina Cima, S.L. Peptidos con capacidad de unirse al factor transformante de crecimiento beta 1 (tgf-b1).
JP5112322B2 (ja) * 2005-10-24 2013-01-09 プロイェクト、デ、ビオメディシナ、シーマ、ソシエダッド、リミターダ 免疫応答調節剤の製造におけるＴＧＦ−β１インヒビターペプチドの使用
US7582609B2 (en) * 2006-03-01 2009-09-01 Digna Biotech, S.L. Method for the treatment of skin fibrosis and suitable compositions for such treatment

Also Published As

Publication number Publication date
CN102791283A (zh) 2012-11-21
US20120315256A1 (en) 2012-12-13
RU2012140704A (ru) 2014-03-27
JP2013520405A (ja) 2013-06-06
WO2011101478A1 (en) 2011-08-25
US20100222280A1 (en) 2010-09-02
CA2790625A1 (en) 2011-08-25
BR112012020953A2 (pt) 2017-02-07
AU2011217181A1 (en) 2012-09-06
US8158589B2 (en) 2012-04-17
EP2538962A1 (en) 2013-01-02

Similar Documents

Publication Publication Date Title
MY158325A (en) Multitype peptide compositions and methods for treatment or prevention of human papillpmavirus infection
MY153766A (en) Derivatised proline containing peptide organic compounds as protease inhibitors
JO2860B1 (en) Phenylendazolyl compounds
TN2012000550A1 (en) THE USE OF sGC STIMULATORS, sGC ACTIVATORS, ALONE AND COMBINATIONS WITH PDE5 INHIBITORS FOR THE TREATMENT OF SYSTEMIC SCLEROSIS (SSc).
MX2019011592A (es) Peptidos y analogos de peptidos protectores de los tejidos para evitar y tratar padecimientos y desordenes asociados con daño de los tejidos.
MX355543B (es) Macrociclos peptidomiméticos.
IL213489A0 (en) Compositions and methods for the treatment of the prevention of e. coli infections and for the eradication or reduction of e. coli surfaces
TN2012000303A1 (en) Oxyntomodulin peptide analogue
ZA201204625B (en) Analogues for the treatment or prevention of flavivirus infections
TN2012000302A1 (en) Oxyntomodulin peptide analogue
HK1198124A1 (en) Dermal filler compositions for fine line treatment
IN2012DN00624A (enExample)
MX2011007930A (es) Conjugados de insulina cristalina.
EP4414376A3 (en) Novel depsipeptide and uses thereof
PH12014501273A1 (en) Intranasal dexmedetomidine compositions and methods of use thereof
MX2011013032A (es) Inhibidores de fosfatidilinositol 3-cinasa.
MX2009011346A (es) Tapentadol para tratamiento de dolor con artritis.
MX359181B (es) Hidrolizado de colágeno y uso del mismo.
GB201118201D0 (en) Novel peptides
MX341020B (es) Peptidos derivados de lactoferrina humana y su uso.
MX2011008179A (es) Peptidos para vacuna.
MY191337A (en) Compositions for the treatment of hypertension and/or fibrosis
WO2009158238A3 (en) Fibroblast growth factor (fgf) analogs and uses thereof
EP3449917A3 (en) Tapentadol for preventing chronification of pain
WO2011119833A3 (en) Bmp-7 peptides & methods of use

Legal Events

Date Code Title Description
FA Abandonment or withdrawal